CAMBRIDGE, Mass., Oct. 26, 2022 (GLOBE NEWSWIRE) — Editas Drugs, Inc. (Nasdaq: EDIT), a scientific stage genome modifying firm, right this moment introduced that it’ll host a convention name and webcast on Wednesday, November 2, 2022, at 8:00 a.m. ET to supply a company replace and outcomes for the third quarter of 2022.
To entry the convention name:
- U.S. callers ought to dial 877-407-0989 and worldwide callers ought to dial 201-389-0921 roughly 5 minutes earlier than the decision begins.
- Contributors ought to ask to be related to the Editas Drugs Earnings Convention Name.
The convention name may even be webcast and could be accessed from the “Buyers” part of the Editas Drugs web site at https://www.editasmedicine.com. A replay of the decision can be obtainable on the similar website roughly one hour after the completion of the decision.
About Editas Drugs
As a scientific stage genome modifying firm, Editas Drugs is concentrated on translating the facility and potential of the CRISPR/Cas9 and CRISPR/Cas12a genome modifying methods into a strong pipeline of remedies for individuals dwelling with severe illnesses all over the world. Editas Drugs goals to find, develop, manufacture, and commercialize transformative, sturdy, precision genomic medicines for a broad class of illnesses. Editas Drugs is the unique licensee of Broad Institute and Harvard College’s Cas9 patent estates and Broad Institute’s Cas12a patent property for human medicines. For the most recent data and scientific displays, please go to www.editasmedicine.com.